CYP17 gene promoter allelic variant is not associated with prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 4, 2003, Pages 262-265

  Lin, Cheng Chieh ^a   Wu, Hsi Chin ^a   Chen, Wen Chi ^a   Chen, Huey Yi ^a,b   Tsai, Fuu Jen ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

CYP17 gene; Cytochrome p450c17 enzyme; Prostate cancer; Single nucleotide polymorphisms (SNPs)

Indexed keywords

CYTOCHROME P450 17; PRIMER DNA; STEROID 17ALPHA MONOOXYGENASE;

5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYP17 GENE; DISEASE ASSOCIATION; DISEASE MARKER; DNA POLYMORPHISM; GENE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; 3' UNTRANSLATED REGION; CELL DIFFERENTIATION; COMPARATIVE STUDY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; AGED; AGED, 80 AND OVER; ALLELES; CELL DIFFERENTIATION; DNA PRIMERS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; VARIATION (GENETICS);

EID: 0142186718     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00276-4     Document Type: Article

References (22)

1. Horoszewicz J.S., Leong S.S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1983;1809-1818
2. Berns E.M., de Boer W., Mulder E. Androgen-dependent growth regulation and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate. 9:1986;247-259
3. Lyss A.P. Systemic treatment for prostate cancer. Am J Med. 83:1987;1120-1128
4. Kyprianou N., English H.F., Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50:1990;3748-3753
5. Picado-Leonard J., Miller W.L. Cloning and sequence of the human gene for P450c17 (steroid 17 α-hydroxylase/17, 20 lyase) similarity with the gene for P450c21. DNA. 6:1987;439-448
6. Habuchi T., Liqing Z., Suzuki T., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60:2000;5710-5713
7. Carey A.H., Waterworth D., Patel K., et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 3:1994;1873-1876
8. Gsur A., Bernhofer G., Hinteregger S., et al. A polymorphism in the CYP117 gene is associated with prostate cancer risk. Int J cancer. 87:2000;434-437
9. Feigelson H.S., Coetzee G.A., Kolonel L.N., Ross R.K., Henderson B.E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57:1997;1063-1065
10. Bergman-Jungestrom M., Gentile M., Lundin A.C., Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J cancer. 84:1999;350-353
11. Aus G., Abbou C.C., Pacik D., et al. EAU guidelines on prostate cancer. Eur Urol. 40:2001;97-101
12. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT a multigenic study on cancer susceptibility. Cancer Res. 59:1999;4870-4875
13. Miller W.L. Early steps in androgen biosynthesis from cholesterol to DHEA. Bailleres Clin Endocrinol Metab. 12:1998;67-81
14. Waterman M.R., Keeney D.S. Genes involved in androgen biosynthesis and the male phenotype. Horm Res. 138:1992;217-221
15. Feigelson H.S., Shames L.S., Pike M.C., Coetzee G.A., Staczyk F.Z., Henderson B.E. Cytochrome P350c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58:1998;585-587
16. Haiman C.A., Hankinson S.E., Spiegelman D., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 59:1999;1015-1020
17. Diamanti-Kandarakis E., Bartzis M.I., Zapanti E.D., et al. Polymorphism T->C (-34bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril. 71:1999;431-435
18. Wadelius M., Andersson A.O., Johansson J.E., Waldelius C., Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics. 9:1999;635-639
19. Kristensen V.N., Haraldsen E.K., Anderson K.B., et al. CYP17 and breast cancer risk the polymorphism in the 5′ flanking area of the gene does not influence binding to SP-1. Cancer Res. 59:1999;2825-2829
20. Haiman C.A., Stampfer M.J., Giovannucci E., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev. 10:2001;743-748
21. Dunning A.M., Healey C.S., Pharoah P.D. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer. 77:1998;2045-2047
22. Latil A.G., Azzouzi R., Cancel G.S., et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 92:2001;1130-1137